1. Home
  2. SNX vs CINGW Comparison

SNX vs CINGW Comparison

Compare SNX & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNX
  • CINGW
  • Stock Information
  • Founded
  • SNX 1980
  • CINGW N/A
  • Country
  • SNX United States
  • CINGW United States
  • Employees
  • SNX N/A
  • CINGW 13
  • Industry
  • SNX Retail: Computer Software & Peripheral Equipment
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • SNX Technology
  • CINGW Health Care
  • Exchange
  • SNX Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • SNX N/A
  • CINGW N/A
  • IPO Year
  • SNX 2003
  • CINGW 2021
  • Fundamental
  • Price
  • SNX $110.73
  • CINGW $0.04
  • Analyst Decision
  • SNX Strong Buy
  • CINGW
  • Analyst Count
  • SNX 9
  • CINGW 0
  • Target Price
  • SNX $137.22
  • CINGW N/A
  • AVG Volume (30 Days)
  • SNX 1.3M
  • CINGW N/A
  • Earning Date
  • SNX 06-24-2025
  • CINGW N/A
  • Dividend Yield
  • SNX 1.59%
  • CINGW N/A
  • EPS Growth
  • SNX 16.43
  • CINGW N/A
  • EPS
  • SNX 8.00
  • CINGW N/A
  • Revenue
  • SNX $59,008,890,000.00
  • CINGW N/A
  • Revenue This Year
  • SNX $3.20
  • CINGW N/A
  • Revenue Next Year
  • SNX $4.26
  • CINGW N/A
  • P/E Ratio
  • SNX $13.80
  • CINGW N/A
  • Revenue Growth
  • SNX 4.62
  • CINGW N/A
  • 52 Week Low
  • SNX $92.23
  • CINGW N/A
  • 52 Week High
  • SNX $145.10
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • SNX 50.55
  • CINGW N/A
  • Support Level
  • SNX $102.16
  • CINGW N/A
  • Resistance Level
  • SNX $110.77
  • CINGW N/A
  • Average True Range (ATR)
  • SNX 3.98
  • CINGW 0.00
  • MACD
  • SNX 2.10
  • CINGW 0.00
  • Stochastic Oscillator
  • SNX 91.42
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: